AA
RLMD icon

ALPS Advisors’s Relmada Therapeutics RLMD Stock Holding History

ALPS Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$737K Buy
+106,456
New +$744K ﹤0.01% 794

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ALPS Advisors's RLMD Position: Q2 2026 in Review

ALPS Advisors opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 106,456 shares worth $737K. The stake represents ﹤0.01% of the portfolio and ranks #794 among its holdings.

126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • ALPS Advisors held 106,456 shares of Relmada Therapeutics worth $737K as of Q2 2026.
  • Relmada Therapeutics was a new ALPS Advisors position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #794 holding.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.